Trichorrhexis Invaginata (Netherton Syndrome or Bamboo Hair) Treatment & Management
- Author: Tina S Chen, MD; Chief Editor: Dirk M Elston, MD more...
Medical Care
Management is conservative. Emollients, keratolytics, and antibiotics are the mainstay of treatment in Netherton syndrome. White, soft paraffin and liquid paraffin in a ratio of 50:50 have been used as a topical treatment.
- Management essentially relies on the treatment of cutaneous infections and other complications.
- Topical steroids of moderate potency are helpful, but reports have described complications such as aminoaciduria and pituitary adrenal axis suppression, especially in patients with widespread erythroderma, and thus should be used with caution.
- In one case, split body treatment with 12% lactic acid lotion surprisingly cleared the eruption on the treated side (control side emollient).[41]
- Although topical tacrolimus or pimecrolimus was previously discouraged in the treatment of Netherton syndrome due to toxicity from absorption of the medication,[42] new evidence suggests that pimecrolimus 1% cream applied twice daily may be well tolerated and lead to improvement of skin involvement, with low, safe levels absorbed systemically.[43] Further, larger studies are necessary to elucidate the safety and efficacy of pimecrolimus in Netherton syndrome patients.[43]
- One Japanese woman's condition has been reported to respond to psoralen plus ultraviolet light A (PUVA).[44]
- Infliximab was found to lead to sustained clinical improvement and clearance of ichthyosis linearis circumflexa in one study[48]
Consultations
- Consult a pediatrician for systemic infections, hypernatremic dehydration, and failure to thrive.
- Consult a gastroenterologist for failure to thrive, diarrhea, and villous atrophy of the small bowel.
- Consult a geneticist for genetic studies and counseling.
Ali M, Marks R, Young E, et al. Netherton's syndrome. A familial occurrence. Br J Dermatol. 1998;226-271.
Comel M. Ichthyosis linearis circumflexa. Dermatologia. 1949.
Fruhwald R. Zur frage der comelschen krankheit. Dermatol Wochenschr. 1949;150:289.
Netherton EW. A unique case of trichorrhexis nodosa; bamboo hairs. AMA Arch Derm. Oct 1958;78(4):483-7. [Medline].
Wilkinson RD, Curtis GH, Hawk WA. Netherton's disease: Trichorhexis invafinata (bamboo hair), congenital ichthyosiform erythroderma and atopic diathesis; a histopatholgic study. Arch Dermatol. Jan 1964;89:46-54. [Medline].
Mevorah B, Frenk E, Brooke EM. Ichthyosis linearis circumflexa comel. A clinico-statistical approach to its relationship with Netherton's syndrome. Dermatologica. 1974;149(4):201-9. [Medline].
Chavanas S, Garner C, Bodemer C, et al. Localization of the Netherton syndrome gene to chromosome 5q32, by linkage analysis and homozygosity mapping. Am J Hum Genet. Mar 2000;66(3):914-21. [Medline].
Namkung JH, Lee JE, Kim E, Byun JY, Kim S, Shin ES, et al. Hint for association of single nucleotide polymorphisms and haplotype in SPINK5 gene with atopic dermatitis in Koreans. Exp Dermatol. Dec 2010;19(12):1048-53. [Medline].
Bonnart C, Deraison C, Lacroix M, Uchida Y, Besson C, Robin A, et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J Clin Invest. Mar 1 2010;120(3):871-82. [Medline]. [Full Text].
Sales KU, Masedunskas A, Bey AL, Rasmussen AL, Weigert R, List K, et al. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome. Nat Genet. Aug 2010;42(8):676-83. [Medline]. [Full Text].
Komatsu N, Saijoh K, Jayakumar A, et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol. May 2008;128(5):1148-59. [Medline].
Jones SK, Thomason LM, Surbrugg SK, Weston WL. Neonatal hypernatraemia in two siblings with Netherton's syndrome. Br J Dermatol. Jun 1986;114(6):741-3. [Medline].
Stoll C, Alembik Y, Tchomakov D, et al. Severe hypernatremic dehydration in an infant with Netherton syndrome. Genet Couns. 2001;12(3):237-43. [Medline].
Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr Dermatol. May-Jun 1996;13(3):183-99. [Medline].
Traupe H. The Ichthyoses. A Guide to Clinical Diagnosis, Genetic Counseling, and Therapy. Berlin: Spirnger Verlag; 1989.
Larregue M, Guillet G. [Collodion baby with neonatal signs of trichothiodystrophy misdiagnosed as Netherton syndrome: reassessment of a previous diagnostic error]. Ann Dermatol Venereol. Mar 2007;134(3 Pt 1):245-8. [Medline].
Neri I, Balestri R, Starace M, Bardazzi F, Patrizi A. Videodermoscopy of eyelashes in Netherton syndrome. J Eur Acad Dermatol Venereol. Nov 25 2010;[Medline].
Goujon E, Beer F, Fraitag S, Hovnanian A, Vabres P. 'Matchstick' eyebrow hairs: a dermoscopic clue to the diagnosis of Netherton syndrome. J Eur Acad Dermatol Venereol. Jun 2010;24(6):740-1. [Medline].
Burk C, Hu S, Lee C, Connelly EA. Netherton syndrome and trichorrhexis invaginata--a novel diagnostic approach. Pediatr Dermatol. Mar-Apr 2008;25(2):287-8. [Medline].
Powell J. Increasing the likelihood of early diagnosis of Netherton syndrome by simple examination of eyebrow hairs. Arch Dermatol. Mar 2000;136(3):423-4. [Medline].
Burk C, Hu S, Lee C, Connelly EA. Netherton syndrome and trichorrhexis invaginata--a novel diagnostic approach. Pediatr Dermatol. Mar-Apr 2008;25(2):287-8. [Medline].
Natsuga K, Akiyama M, Shimizu H. Malignant skin tumours in patients with inherited ichthyosis. Br J Dermatol. Aug 2011;165(2):263-8. [Medline].
Magert HJ, Standker L, Kreutzmann P, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem. Jul 30 1999;274(31):21499-502. [Medline].
Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. Jun 2000;25(2):141-2. [Medline].
Culbertson MR. RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet. Feb 1999;15(2):74-80. [Medline].
Hosomi N, Fukai K, Nakanishi T, Funaki S, Ishii M. Caspase-1 activity of stratum corneum and serum interleukin-18 level are increased in patients with Netherton syndrome. Br J Dermatol. Sep 2008;159(3):744-6. [Medline].
Bitoun E, Micheloni A, Lamant L, et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet. Oct 1 2003;12(19):2417-30. [Medline].
Briot A, Lacroix M, Robin A, Steinhoff M, Deraison C, Hovnanian A. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol. Dec 2010;130(12):2736-42. [Medline].
Bitoun E, Chavanas S, Irvine AD, et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol. Feb 2002;118(2):352-61. [Medline].
Capri Y, Vanlieferinghen P, Boeuf B, Dechelotte P, Hovnanian A, Lecomte B. [A lethal variant of Netherton syndrome in a large inbred family]. Arch Pediatr. Mar 2011;18(3):294-8. [Medline].
Hachem JP, Wagberg F, Schmuth M, et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol. Jul 2006;126(7):1609-21. [Medline].
Komatsu N, Saijoh K, Jayakumar A, et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol. May 2008;128(5):1148-59. [Medline].
Descargues P, Deraison C, Bonnart C, et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet. Jan 2005;37(1):56-65. [Medline].
Goodyear HM, Harper JI. Leiner's disease associated with metabolic acidosis. Clin Exp Dermatol. Sep 1989;14(5):364-6. [Medline].
de Berker DA, Paige DG, Ferguson DJ, Dawber RP. Golf tee hairs in Netherton disease. Pediatr Dermatol. Mar 1995;12(1):7-11. [Medline].
Powell J. Increasing the likelihood of early diagnosis of Netherton syndrome by simple examination of eyebrow hairs. Arch Dermatol. Mar 2000;136(3):423-4. [Medline].
Fartasch M, Williams ML, Elias PM. Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Arch Dermatol. Jul 1999;135(7):823-32. [Medline].
Frenk E, Mevorah B. Ichthyosis linearis circumflexa Comèl with Trichorrhexis invaginata (Netherton's Syndrom): an ultrastructural study of the skin changes. Arch Dermatol Forsch. 1972;245(1):42-9. [Medline].
Komatsu N, Takata M, Otsuki N, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol. Mar 2002;118(3):436-43. [Medline].
Arico M, Leonardo S, Pravata G, et al. Netherton's syndrome in male. An immunohistochemical study. Pediatr Dermatol. 1996;13:183-99.
Wehr RF, Hickman J, Krochmal L. Effective treatment of Netherton's syndrome with 12% lactate lotion. J Am Acad Dermatol. Jul 1988;19(1 Pt 1):140-2. [Medline].
Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. Jun 2001;137(6):747-50. [Medline].
Yan AC, Honig PJ, Ming ME, Weber J, Shah KN. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Arch Dermatol. Jan 2010;146(1):57-62. [Medline].
Nagata T. Netherton's syndrome which responded to photochemotherapy. Dermatologica. 1980;161(1):51-6. [Medline].
Hausser I, Anton-Lamprecht I, Hartschuh W, Petzoldt D. Netherton's syndrome: ultrastructure of the active lesion under retinoid therapy. Arch Dermatol Res. 1989;281(3):165-72. [Medline].
Hartschuh W, Hausser I, Petzoldt D. [Successful retinoid therapy of Netherton syndrome]. Hautarzt. Jul 1989;40(7):430-3. [Medline].
Lazaridou E, Apalla Z, Patsatsi A, Trigoni A, Ioannides D. Netherton's syndrome: successful treatment with isotretinoin. J Eur Acad Dermatol Venereol. Feb 2009;23(2):210-2. [Medline].
Fontao L, Laffitte E, Briot A, Kaya G, Roux-Lombard P, Fraitag S, et al. Infliximab Infusions for Netherton Syndrome: Sustained Clinical Improvement Correlates with a Reduction of Thymic Stromal Lymphopoietin Levels in the Skin. J Invest Dermatol. Jun 9 2011;[Medline].
Di WL, Larcher F, Semenova E, Talbot GE, Harper JI, Del Rio M, et al. Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol Ther. Feb 2011;19(2):408-16. [Medline]. [Full Text].
Roedl D, Oji V, Buters JT, Behrendt H, Braun-Falco M. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients. J Dermatol Sci. Mar 2011;61(3):194-8. [Medline].
Draheim KM, Lyle S. Epithelial stem cells. Methods Mol Biol. 2011;750:261-74. [Medline].
Altman J, Stroud J. Neterton's syndrome and ichthyosis linearis circumflexa. Arch Dermatol. Nov 1969;100(5):550-8. [Medline].

